SIREN : 883601114
IDC PHARMA is a French company founded 5 years ago, specialized in the sector Vente à distance sur catalogue général. Based in LEVALLOIS-PERRET (92300), this company of category PME shows in 2021 a revenue of 26.0 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2021 |
|---|---|
| Revenue | 25 976 682 € |
| Net income | 754 353 € |
| EBITDA | 1 191 267 € |
| Net margin | 2.9% |
In 2021, IDC PHARMA achieves revenue of 26.0 M€. After deducting consumption (21.2 M€), gross margin stands at 4.8 M€, i.e. a rate of 18%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 1.2 M€, representing 4.6% of revenue. The operating margin remains fragile, requiring cost vigilance. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 754 k€, i.e. 2.9% of revenue. This profit can be retained or distributed to shareholders.
25 976 682 €
4 760 307 €
1 191 267 €
1 026 748 €
754 353 €
4.6%
The debt ratio (= Financial debt / Equity x 100) stands at 16%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 11%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.1 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 3.5% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
15.682%
11.13%
3.529%
0.129
63.6%
In 2021, the debt ratio of IDC PHARMA (15.68) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2021, the financial autonomy of IDC PHARMA (11.1%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2021, the repayment capacity of IDC PHARMA (0.13) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 114.44. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
114.441
0.0
In 2021, the liquidity ratio of IDC PHARMA (114.44) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2021, the interest coverage of IDC PHARMA (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 62 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 68 days. Favorable situation: supplier credit is longer than customer credit by 6 days. Overall, WCR represents 64 days of revenue, i.e. 4.6 M€ to permanently finance.
4 611 900 €
62 j
68 j
0 j
64 j
Based on 121 transactions of similar company sales (all years), the value of IDC PHARMA is estimated at 4 568 142 € (range 2 233 596€ - 10 445 855€). With an EBITDA of 1 191 267€, the sector multiple of 3.2x is applied. The price/revenue ratio is 0.27x (conservative valuation). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 121 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare IDC PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Vente à distance sur catalogue général
The revenue of IDC PHARMA in 2021 is 26.0 M€.
Yes, IDC PHARMA generated a net profit of 754 k€ in 2021.
The headquarters of IDC PHARMA is located in LEVALLOIS-PERRET (92300), in the department Hauts-de-Seine.
The tax return of IDC PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
IDC PHARMA operates in the sector Vente à distance sur catalogue général (NAF code 47.91A). See the 'Sector positioning' section above to compare the company with its competitors.